The Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a nonprofit public-private partnership focused on accelerating efforts to address drug-resistant infections, has announced commitments totaling nearly $52 million over three years from the Bill & Melinda Gates Foundation and the government of the United Kingdom.
The commitments include up to $25 million from the Gates Foundation and up to £20 million (nearly $26.9 million) from the UK's Global Antimicrobial Resistance Innovation Fund (GAMRIF) in support of early-stage development of antibiotics, vaccines, and diagnostics designed to fight superbugs. According to CARB-X, drug-resistant infections are responsible for seven hundred thousand deaths worldwide each year.
Launched in 2016 by the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases and based at the Boston University School of Law, CARB-X has over thirty-three projects in its portfolio and, with the latest commitments — announced at the launch of the Global Antimicrobial Resistance R&D Hub during the 71st World Health Assembly meeting in Geneva — has secured more than $500 million in funding.
"The threat of antimicrobial resistance underscores the importance of prevention — which we believe is key to saving lives," said Gates Foundation CEO Sue Desmond-Hellmann. "The Gates Foundation funding will advance the development of vaccines and novel biologics, including monoclonal antibodies, to avert drug-resistant diseases and protect the lives of children and infants, especially in low- and middle-income countries."
(Photo credit: James Archer/CDC)